MIRA
INFORM REPORT
|
Report Date : |
12.02.2008 |
IDENTIFICATION
DETAILS
|
Name : |
AMRIYA PHARMACEUTICAL INDUSTRIES |
|
|
|
|
Registered Office : |
3a El Moaskar El Romany Street, Rushdy, Ramleh, PO Box 111, Alexandria |
|
|
|
|
Country : |
Egypt |
|
|
|
|
Date of Incorporation : |
1984 |
|
|
|
|
Com. Reg. No.: |
112775, Alexandria |
|
|
|
|
Legal Form : |
Egyptian Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacture and Export of
Pharmaceuticals and Medical Preparations. |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
US$ 400,000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
SUMMARY
Company Name : AMRIYA PHARMACEUTICAL INDUSTRIES
Country of Origin : Egypt
Legal Form : Egyptian Joint Stock Company
Registration Date : 1984
Commercial Registration Number : 112775, Alexandria
Authorised Capital : £E 300,000,000
Issued Capital : £E 216,000,000
Paid up Capital : £E 216,000,000
Total Workforce : 150
Line of Business :
Manufacture and export of pharmaceuticals and medical
preparations.
Financial Condition : Undetermined
Payments : Nothing detrimental uncovered
COMPANY NAME
AMRIYA PHARMACEUTICAL INDUSTRIES
ADDRESS
Registered & Physical Address
Street : 3a El Moaskar El Romany Street
Area : Rushdy, Ramleh
PO Box : 111
Town : Alexandria
Country : Egypt
Telephone : (20-2) 5431799
Facsimile : (20-2) 5431799
Premises
Subject operates from a medium sized suite of offices that are rented and
located in the Central Business Area of Alexandria.
Branch Office (s)
Location Description
· Alexandria
Cairo Desert Road, Km 25 Owned
factory premises
Amreya
Alexandria
Tel:
(20-3) 4701001 / 4701150
Fax:
(20-3) 4701003 / 4701153
· 15 El Nozha
Street Rented
sales office
Nasr City
Cairo
Tel:
(20-2) 4181821
KEY PRINCIPALS
· Dr.
Hassan Abbass Helmy Chairman
· Dr.
Shereen Hassan Abbass Helmy Vice
Chairman
· Abd El
Moniem El Tokhy Director
· Dr.
Mohamed Ali Hassan El Ebeary Director
· Yashar
Hassan Abbass Director
· Mamdouh
Abbass Ibrahim Director
· Ahmed
Amin Hassan Director
· Mohamed
Ibrahim Hamza Director
· Said
Ahmed Khalil Director
· Ali
Feteiha Finance
Manager
· Dr.
Yasser Fayed Sales
Manager
LEGAL FORM & OWNERS
Date of Establishment : 1984
Legal Form : Societe Anonyme
Egyptienne – SAE (Egyptian Joint Stock Company)
Commercial Reg. No. : 112775, Alexandria
Authorised Capital : £E 300,000,000
Issued Capital : £E 216,000,000
Paid up Capital : £E 216,000,000
Name of Shareholder (s)
· Pharco
Pharmaceuticals Group
Borg El Arab
Alexandria
Tel : (20-3)
4480130 / 4480140
Fax : (20-3)
4480730
· Dr Hassan Abbass
Helmy
· Dr Sherien Hassan
Abbass Helmy
Note to the Legal Form
The Egyptian Company Law provides that the capital of a
Societe Anonyme Egyptienne - SAE – should not be less than £E 500,000 if shares
are offered to the public and £E 250,000 if not. If shares are offered to the
public they are freely transferable, if not, transfer may be restricted.
Liability of shareholders is limited.
AFFILIATED COMPANIES
· European
Pharmaceutical Industries
Desert
Road, Km 25
Elmanshia,
Amriya
Alexandria
Tel:
(20-3) 4701001
Fax:
(20-3) 4701003
Email: sherien@pharco.com.eg
LINE OF BUSINESS
Operations : Engaged in the
manufacture and export of pharmaceuticals and medical
preparations with 109 preparations,
for human use, as well as specialty food and veterinary products.
Subject’s range is produced
under license of Synthelabo (France) and Weimer (Germany).
The company is ISO
14001 and ISO 9001 registered..
Import Countries : Germany, France and Japan.
Export Countries : Saudi Arabia, Yemen,
Libya, and Sudan.
Subject has a workforce of 150 employees.
FINANCIAL HIGHLIGHTS
Companies registered in Egypt are not legally required to make their accounts
public and no financial information was released by the company or submitted by
outside sources.
BANKERS
·
Citibank
95, 26th July Street
Azarita
Alexandria
Tel : (20-3) 4834363 / 4840342
Fax : (20-3) 4884363
·
Misr International Bank (MIBANK)
33, Safia Zaghloul
Street
Raml Station
Alexandria
Tel : (20-3)
4828174 / 4828213
Fax : (20-3) 4838216
·
Commercial International Bank (CIB)
61 Sultan Hussein Street
Alexandria
Tel : (20-3) 4824643 / 4834255
Fax : (20-3) 4832240
·
National Societe Generale Bank
240 El Corniche
Street
Roushdy, Ramleh
Alexandria
Tel: (20-3)
5452352
Fax: (20-3)
5455715
PAYMENT HISTORY
No complaints regarding subject’s payments have been reported.
Date of transaction July
2005
Credit amount 100,000
Amount overdue 0
Payment terms 60
days
Payment Method Letters
of Credit
Paying record No
Complaints
Currency US
Dollars
GENERAL COMMENTS
Amriya Pharmaceutical Industries has been in business for over 20 years
and is engaged in the manufacture and export of
pharmaceuticals and medical preparations.
During the course of this investigation nothing detrimental was
uncovered regarding subject’s operating history or the manner in which payments
are fulfilled. As such the company is considered to be a fair trade risk and
the above credit figure is within subject’s financial means.
Maximum suggested credit figure: US$ 400,000
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)